guanfacine has been researched along with Suicidal Ideation in 3 studies
Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.
Suicidal Ideation: A risk factor for suicide attempts and completions, it is the most common of all suicidal behavior, but only a minority of ideators engage in overt self-harm.
Excerpt | Relevance | Reference |
---|---|---|
"Youth aged 6-17 years with a primary diagnosis of GAD, SAD, and/or social anxiety disorder were treated with flexibly dosed GXR (1-6 mg daily, n = 62) or placebo (n = 21) for 12 weeks." | 6.84 | Extended Release Guanfacine in Pediatric Anxiety Disorders: A Pilot, Randomized, Placebo-Controlled Trial. ( Albano, AM; Compton, SN; Hamdani, M; Robertson, B; Rynn, MA; Strawn, JR, 2017) |
"Youth aged 6-17 years with a primary diagnosis of GAD, SAD, and/or social anxiety disorder were treated with flexibly dosed GXR (1-6 mg daily, n = 62) or placebo (n = 21) for 12 weeks." | 2.84 | Extended Release Guanfacine in Pediatric Anxiety Disorders: A Pilot, Randomized, Placebo-Controlled Trial. ( Albano, AM; Compton, SN; Hamdani, M; Robertson, B; Rynn, MA; Strawn, JR, 2017) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Nikou, AF | 1 |
Lai, M | 1 |
Solmssen, C | 1 |
Bhargava, M | 1 |
Ben-David, K | 1 |
Ramsubick, C | 1 |
Rice, T | 2 |
Coffey, B | 1 |
Weiss-Goldman, N | 1 |
Arditi, B | 1 |
Coffey, BJ | 1 |
Strawn, JR | 1 |
Compton, SN | 1 |
Robertson, B | 1 |
Albano, AM | 1 |
Hamdani, M | 1 |
Rynn, MA | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).[NCT01470469] | Phase 2 | 83 participants (Actual) | Interventional | 2012-01-04 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
(NCT01470469)
Timeframe: Baseline and up to 12 weeks
Intervention | mmHg (Mean) |
---|---|
PLACEBO | 0.9 |
SPD503 | -1.3 |
The QT interval is the time from the start of the Q wave to the end of the T wave. It is a portion of the ECG tracing that represents the time taken for ventricular depolarisation and repolarisation. The QTcF includes a correction factor to help account for changes in heart rate. (NCT01470469)
Timeframe: Baseline and up to 12 weeks
Intervention | msec (Mean) |
---|---|
PLACEBO | 0.3 |
SPD503 | 4.1 |
QRS complex is a portion of the ECG tracing that represents depolarization of the ventricular myocardium. (NCT01470469)
Timeframe: Baseline and up to 12 weeks
Intervention | msec (Mean) |
---|---|
PLACEBO | 0.7 |
SPD503 | 0.1 |
(NCT01470469)
Timeframe: Baseline and up to 12 weeks
Intervention | cm (Mean) |
---|---|
PLACEBO | 0.5 |
SPD503 | 1.0 |
(NCT01470469)
Timeframe: Baseline and up to 12 weeks
Intervention | beats/min (Mean) |
---|---|
PLACEBO | -0.5 |
SPD503 | -1.8 |
(NCT01470469)
Timeframe: Baseline and up to 12 weeks
Intervention | mmHg (Mean) |
---|---|
PLACEBO | -1.7 |
SPD503 | -2.3 |
(NCT01470469)
Timeframe: Baseline and up to 12 weeks
Intervention | kg (Mean) |
---|---|
PLACEBO | 0.7 |
SPD503 | 1.3 |
1 trial available for guanfacine and Suicidal Ideation
Article | Year |
---|---|
Extended Release Guanfacine in Pediatric Anxiety Disorders: A Pilot, Randomized, Placebo-Controlled Trial.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Anxiety Disorders; Anxiety, Separation; Child; Del | 2017 |
2 other studies available for guanfacine and Suicidal Ideation
Article | Year |
---|---|
Topiramate for Posttraumatic Symptoms in an Obese Adolescent Girl.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Anticonvulsants; Antipsychotic Agents; Depression; | 2021 |
Psychopharmacology of the Rage Attack Phenomenon in a Child with Obsessive Compulsive Disorder.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Attention Deficit Disorder with Hyperactivity; Fem | 2018 |